AbbVie, riding the Aduhelm afterglow, handpicks beta amyloid drug for further R&D as it bails on tau
Although shrouded in controversy, the FDA’s approval of Biogen’s Aduhelm for Alzheimer’s disease has opened the floodgates for other drugmakers buying in on the anti-amyloid hypothesis underscoring the drug’s success. You can now count drug giant AbbVie among them.
On an earnings call with analysts Friday, AbbVie $ABBV revealed its plans to advance a handpicked beta amyloid targeting molecule for Alzheimer’s disease while abandoning development of its Phase II tau program ABBV-8E12.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,500+ biopharma pros reading Endpoints daily — and it's free.